Effect of androgen replacement therapy on atherosclerotic risk markers in young-to-middle-aged men with idiopathic hypogonadotropic hypogonadism

Clinical Endocrinology

Volumn 82, Issue 3, 2015, Pages 422-428

  Doʇan, Berҫem Ayҫiҫek ^a   Karakiliҫ, Ersen ^b   Tuna, Mazhar Müslüm ^c   Arduҫ, Ayşe ^d   Berker, Dilek ^b   Güler, Serdar ^e  

^a Darica Farabi State Hospital   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e HITIT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOTROPIN; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; HOMOCYSTEINE; HYDROCORTISONE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANDROGEN THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FREE THYROXINE INDEX; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; MALE; MIDDLE AGED; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; YOUNG ADULT; ALGORITHM; BLOOD; HORMONE SUBSTITUTION; HYPOGONADISM; PROCEDURES;

ADULT; ALGORITHMS; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 84923039350     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12617     Document Type: Article

References (43)

1. Bianco, S.D., &, Kaiser, U.B., (2009) The genetic and molecular basis of hypogonadotropic hypogonadism. Nature Reviews. Endocrinology, 5, 569-576.
2. Maggio, M., Lauretani, F., Ceda, G.P., et al,. (2007) Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Archives of Internal Medicine, 167, 2249-2254.
3. Khaw, K., Dowsett, M., Folkerd, E., et al,. (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation, 116, 2694-2701.
4. Liu, P.Y., Death, A.K., &, Handelsman, D.J., (2003) Androgens and cardiovascular disease. Endocrine Reviews, 24, 313-340.
5. Laughlin, G.A., Barrett-Connor, E., &, Bergstrom, J., (2008) Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology and Metabolism, 93, 68-75.
6. Maggio, M., Basaria, S., &, Ble, A., (2006) Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. Journal of Clinical Endocrinology and Metabolism, 91, 345-347.
7. Basaria, S., (2008) Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. Journal of Andrology, 29, 534-539.
8. Mäkinen, J.I., Perheentupa, A., Irjala, K., et al,. (2008) Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis, 197, 688-693.
9. Shahani, S., Braga-Basaria, M., &, Basaria, S., (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 93, 2042-2049.
10. Jones, T.H., &, Saad, F., (2009) The effects of testosterone on risk factors for, and the mediators of the atherosclerotic process. Atherosclerosis, 207, 318-327.
11. Kim, J., Montagnani, M., Koh, K., et al,. (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation, 113, 1888-1904.
12. Saad, F., Gooren, L., Haider, A., et al,. (2007) An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Archives of Andrology, 53, 353-357.
13. Barud, W., Palusinski, R., Beltkowski, J., et al,. (2002) Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis, 164, 282-288.
14. Mäkinen, J., Jarvisalo, M., Pollanen, P., et al,. (2005) Increased carotid atherosclerosis in andropausal middle-aged men. Journal of the American College of Cardiology, 45, 1603-1608.
15. Fu, L., Gao, Q.P., &, Shen, J.X., (2008) Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian Journal of Andrology, 10, 214-218.
16. Traish, A.M., Saad, F., &, Guay, A.T., (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. Journal of Andrology, 30, 23-32.
17. Higashi, Y., Noma, K., Yoshizumi, M., et al,. (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circulation Journal, 73, 411-418.
18. Muller, M., vanden Beld, A.W., Bot, M.L., et al,. (2004) Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 109, 2074-2079.
19. Zitzmann, M., Vorona, E., Wenk, M., et al,. (2008) Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle aged overweight men. Journal of Andrology, 29 (Suppl 1), 54-55.
20. Heitzer, T., Schlinzig, T., Krohn, K., et al,. (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 104, 2673-2678.
21. Bhasin, S., Cunningham, G.R., Hayes, F.J., et al,. (2010) Testosterone therapy in adult men with androgen deficiency syndromes; an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
22. The Society of Endocrinology and Metabolism of Turkey (2014) Guidelines of Diagnosis and Treatment of Adrenal and Gonadal Disease. In: Adrenal ve Gonadal Hastaliklar Kilavuzu, 7th Ed., Ankara, Turkey. ISBN:978-605-4011-20-9
23. Harris, R.A., Nishiyama, S.K., Wray, D.W., et al,. (2010) Ultrasound assessment of flow-mediated dilation. Hypertension, 55, 1075-1085.
24. Vogel, R.A., Coretti, M.C., &, Plotnick, G.D., (1996) Changes in flow-mediated brachial artery vasoreactivity with lowering of desirable cholesterol levels in healthy middle-aged men. American Journal of Cardiology, 77, 37-40.
25. Kapoor, D., Clarke, S., Stanworth, R., et al,. (2007) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 156, 595-602.
26. Vigen, R., O'Donnell, C.I., Barõn, A.E., et al,. (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310, 1829-1836.
27. Xu, L., Freeman, G., Cowling, B.J., et al,. (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine, 11, 108.
28. Aversa, A., Bruzziches, R., Francomano, D., et al,. (2010) Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. The Journal of Sexual Medicine, 10, 3495-3503.
29. Kalinchenko, S.Y., Tishova, Y.A., Mskhalaya, G.J., et al,. (2010) Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clinical Endocrinology, 73, 602-612.
30. Hak, A., Witteman, J., de Jong, F., et al,. (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. Journal of Clinical Endocrinology and Metabolism, 87, 3632-3639.
31. Laaksonen, D.E., Niskanen, L., Punnonen, K., et al,. (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. European Journal of Endocrinology, 149, 601-608.
32. Haddad, R.M., Kennedy, C.C., Caples, S.M., et al,. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings, 82, 29-39.
33. Ng, M.K.C., Liu, P.Y., Williams, A.J., et al,. (2002) Prospective study of effect of androgens on serum inflammatory markers in men. Arteriosclerosis, Thrombosis, and Vascular Biology, 7, 1136-1141.
34. Haring, R., Völzke, H., Steveling, A., et al,. (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. European Heart Journal, 31, 1494-1501.
35. Van Pottelbergh, I., Braeckman, L., De Bacquer, D., et al,. (2003) Potential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis, 166, 95-102.
36. Zitzmann, M., &, Nieschlag, E., (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 92, 3844-3853.
37. Saad, F., Gooren, L.J., Haider, A., et al,. (2008) A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology, 29, 102-105.
38. Zgliczynski, S., Ossowski, M., Slowinska-Srzednicka, J., et al,. (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis, 121, 35-43.
39. Uyanik, B.S., Ari, Z., Gumus, B., et al,. (1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Japanese Heart Journal, 38, 73-82.
40. Thompson, P.D., Cullinane, E.M., Sady, S.P., et al,. (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA, 261, 1165-1168.
41. Bagatell, C.J., Heiman, J.R., Matsumoto, A.M., et al,. (1994) Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. Journal of Clinical Endocrinology and Metabolism, 79, 561-567.
42. Webb, C., Elkington, A., Kraidly, M., et al,. (2008) Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. American Journal of Cardiology, 101, 618-624.
43. Sader, M.A., Griffiths, K.A., Skilton, M.R., et al,. (2003) Physiological testosterone replacement and arterial endothelial function in men. Clinical Endocrinology, 59, 62-67.